In our study, the proportion of EZH2-expressing cells was the highest in the subpopulation with the worst prognosis (hypopharyngeal carcinoma patients) and the lowest in those with the best DFS rates (laryngeal carcinoma patients). This evidence concerns the gene EZH2 and hypopharyngeal carcinoma.